Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111


NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.

Bertucci F, Rypens C, Finetti P, Guille A, Adelaïde J, Monneur A, Carbuccia N, Garnier S, Dirix P, Gonçalves A, Vermeulen P, Debeb BG, Wang X, Dirix L, Ueno NT, Viens P, Cristofanilli M, Chaffanet M, Birnbaum D, Van Laere S.

Mol Oncol. 2019 Dec 19. doi: 10.1002/1878-0261.12621. [Epub ahead of print]


Targeted molecular characterization shows differences between primary and secondary myelofibrosis.

Courtier F, Garnier S, Carbuccia N, Guille A, Adélaide J, Chaffanet M, Hirsch P, Paz DL, Slama B, Vey N, Ugo V, Delhommeau F, Rey J, Birnbaum D, Murati A.

Genes Chromosomes Cancer. 2019 Jul 24. doi: 10.1002/gcc.22789. [Epub ahead of print]


Author Correction: Genomic characterization of metastatic breast cancers.

Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F.

Nature. 2019 Aug;572(7767):E7. doi: 10.1038/s41586-019-1380-3.


Genomic characterization of metastatic breast cancers.

Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F.

Nature. 2019 May;569(7757):560-564. doi: 10.1038/s41586-019-1056-z. Epub 2019 May 22. Erratum in: Nature. 2019 Aug;572(7767):E7.


A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases.

Tyran M, Carbuccia N, Garnier S, Guille A, Adelaïde J, Finetti P, Toulzian J, Viens P, Tallet A, Goncalves A, Metellus P, Birnbaum D, Chaffanet M, Bertucci F.

Cancers (Basel). 2019 May 13;11(5). pii: E665. doi: 10.3390/cancers11050665.


Inflammatory breast cancer in 210 patients: A retrospective study on epidemiological, anatomo-clinical features and therapeutic results.

Manai M, Finetti P, Mejri N, Athimni S, Birnbaum D, Bertucci F, Rahal K, Gamoudi A, Chaffanet M, Manai M, Boussen H.

Mol Clin Oncol. 2019 Feb;10(2):223-230. doi: 10.3892/mco.2018.1773. Epub 2018 Nov 26.


Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.

Xerri L, Adélaïde J, Avenin M, Guille A, Taix S, Bonnet N, Carbuccia N, Garnier S, Mescam L, Murati A, Chaffanet M, Coso D, Bouabdallah R, Bertucci F, Birnbaum D.

Histopathology. 2019 Mar;74(4):654-662. doi: 10.1111/his.13783. Epub 2019 Jan 31.


Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value.

Doghri R, Manai M, Finetti P, Driss M, Agavnian E, Lopez M, Elghardallou M, Charafe-Jauffret E, Manai M, Chaffanet M, Birnbaum D, Mrad K, Bertucci F.

Int J Mol Sci. 2017 Dec 23;19(1). pii: E41. doi: 10.3390/ijms19010041.


CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors.

Xerri L, Adélaïde J, Popovici C, Garnier S, Guille A, Mescam-Mancini L, Laurent C, Brousset P, Coze C, Michel G, Chaffanet M, Bouabdallah R, Coso D, Bertucci F, Birnbaum D.

Am J Surg Pathol. 2018 Feb;42(2):150-159. doi: 10.1097/PAS.0000000000000989.


Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification.

Cervera N, Carbuccia N, Mozziconacci MJ, Adélaïde J, Garnier S, Guille A, Murati A, Chaffanet M, Vey N, Birnbaum D, Gelsi-Boyer V.

Blood Cancer J. 2017 Aug 25;7(8):e594. doi: 10.1038/bcj.2017.68. No abstract available.


An ICGC major achievement in breast cancer: a comprehensive catalog of mutations and mutational signatures.

Bertucci F, Chaffanet M, Birnbaum D.

Chin Clin Oncol. 2017 Feb;6(1):4. doi: 10.21037/cco.2016.11.01. Epub 2016 Nov 9. No abstract available.


MARCKS protein overexpression in inflammatory breast cancer.

Manai M, Thomassin-Piana J, Gamoudi A, Finetti P, Lopez M, Eghozzi R, Ayadi S, Lamine OB, Manai M, Rahal K, Charafe-Jauffret E, Jacquemier J, Viens P, Birnbaum D, Boussen H, Chaffanet M, Bertucci F.

Oncotarget. 2017 Jan 24;8(4):6246-6257. doi: 10.18632/oncotarget.14057.


Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.

Gonçalves A, Bertucci F, Guille A, Garnier S, Adelaide J, Carbuccia N, Cabaud O, Finetti P, Brunelle S, Piana G, Tomassin-Piana J, Paciencia M, Lambaudie E, Popovici C, Sabatier R, Tarpin C, Provansal M, Extra JM, Eisinger F, Sobol H, Viens P, Lopez M, Ginestier C, Charafe-Jauffret E, Chaffanet M, Birnbaum D.

Oncotarget. 2016 Nov 29;7(48):79428-79441. doi: 10.18632/oncotarget.12714.


Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.

Courtier F, Carbuccia N, Garnier S, Guille A, Adélaïde J, Cervera N, Gelsi-Boyer V, Mozziconacci MJ, Rey J, Vey N, Chaffanet M, Birnbaum D, Murati A.

Haematologica. 2017 Jan;102(1):e11-e14. doi: 10.3324/haematol.2016.152363. Epub 2016 Oct 14. No abstract available.


Epigenetically centered evolution in an example of myeloid malignancy.

Adélaide J, Cervera N, Carbuccia N, Garnier S, Guille A, Mozziconnaci MJ, Devillier R, Chaffanet M, Vey N, Birnbaum D, Gelsi-Boyer V.

Am J Hematol. 2016 Sep;91(9):E361-2. doi: 10.1002/ajh.24450. Epub 2016 Jul 4. No abstract available.


Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma.

Birnbaum DJ, Bertucci F, Finetti P, Adélaïde J, Giovannini M, Turrini O, Delpero JR, Raoul JL, Chaffanet M, Moutardier V, Birnbaum D, Mamessier E.

Cancer Genomics Proteomics. 2016 May-Jun;13(3):191-200.


Comparative genomic analysis of primary tumors and metastases in breast cancer.

Bertucci F, Finetti P, Guille A, Adélaïde J, Garnier S, Carbuccia N, Monneur A, Charafe-Jauffret E, Goncalves A, Viens P, Birnbaum D, Chaffanet M.

Oncotarget. 2016 May 10;7(19):27208-19. doi: 10.18632/oncotarget.8349.


Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer.

Puvirajesinghe TM, Bertucci F, Jain A, Scerbo P, Belotti E, Audebert S, Sebbagh M, Lopez M, Brech A, Finetti P, Charafe-Jauffret E, Chaffanet M, Castellano R, Restouin A, Marchetto S, Collette Y, Gonçalvès A, Macara I, Birnbaum D, Kodjabachian L, Johansen T, Borg JP.

Nat Commun. 2016 Jan 12;7:10318. doi: 10.1038/ncomms10318.


pH-Cleavable Nucleoside Lipids: A New Paradigm for Controlling the Stability of Lipid-Based Delivery Systems.

Oumzil K, Benizri S, Tonelli G, Staedel C, Appavoo A, Chaffanet M, Navailles L, Barthélémy P.

ChemMedChem. 2015 Nov;10(11):1797-801. doi: 10.1002/cmdc.201500381. Epub 2015 Sep 18.


Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing.

Cervera N, Carbuccia N, Garnier S, Guille A, Adélaïde J, Murati A, Vey N, Mozziconacci MJ, Chaffanet M, Birnbaum D, Gelsi-Boyer V.

Leukemia. 2016 Apr;30(4):966-70. doi: 10.1038/leu.2015.198. Epub 2015 Jul 23. No abstract available.


Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.

Collette Y, Prébet T, Goubard A, Adélaïde J, Castellano R, Carbuccia N, Garnier S, Guille A, Arnoulet C, Charbonier A, Mozziconacci MJ, Birnbaum D, Chaffanet M, Vey N.

Blood Cancer J. 2015 Mar 13;5:e292. doi: 10.1038/bcj.2015.13. No abstract available.


Prognostic and predictive value of PDL1 expression in breast cancer.

Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D, Bertucci F.

Oncotarget. 2015 Mar 10;6(7):5449-64.


Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.

Sabatier R, Finetti P, Guille A, Adelaide J, Chaffanet M, Viens P, Birnbaum D, Bertucci F.

Mol Cancer. 2014 Oct 2;13:228. doi: 10.1186/1476-4598-13-228.


ESPL1 is a candidate oncogene of luminal B breast cancers.

Finetti P, Guille A, Adelaide J, Birnbaum D, Chaffanet M, Bertucci F.

Breast Cancer Res Treat. 2014 Aug;147(1):51-9. doi: 10.1007/s10549-014-3070-z. Epub 2014 Aug 3.


Brief reports: A distinct DNA methylation signature defines breast cancer stem cells and predicts cancer outcome.

El Helou R, Wicinski J, Guille A, Adélaïde J, Finetti P, Bertucci F, Chaffanet M, Birnbaum D, Charafe-Jauffret E, Ginestier C.

Stem Cells. 2014 Nov;32(11):3031-6. doi: 10.1002/stem.1792.


Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling.

Cornen S, Guille A, Adélaïde J, Addou-Klouche L, Finetti P, Saade MR, Manai M, Carbuccia N, Bekhouche I, Letessier A, Raynaud S, Charafe-Jauffret E, Jacquemier J, Spicuglia S, de The H, Viens P, Bertucci F, Birnbaum D, Chaffanet M.

PLoS One. 2014 Jan 9;9(1):e81843. doi: 10.1371/journal.pone.0081843. eCollection 2014.


Early lesions of follicular lymphoma: a genetic perspective.

Mamessier E, Song JY, Eberle FC, Pack S, Drevet C, Chetaille B, Abdullaev Z, Adelaïde J, Birnbaum D, Chaffanet M, Pittaluga S, Roulland S, Chott A, Jaffe ES, Nadel B.

Haematologica. 2014 Mar;99(3):481-8. doi: 10.3324/haematol.2013.094474. Epub 2013 Oct 25.


ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program.

Charafe-Jauffret E, Ginestier C, Bertucci F, Cabaud O, Wicinski J, Finetti P, Josselin E, Adelaide J, Nguyen TT, Monville F, Jacquemier J, Thomassin-Piana J, Pinna G, Jalaguier A, Lambaudie E, Houvenaeghel G, Xerri L, Harel-Bellan A, Chaffanet M, Viens P, Birnbaum D.

Cancer Res. 2013 Dec 15;73(24):7290-300. doi: 10.1158/0008-5472.CAN-12-4704. Epub 2013 Oct 18.


Integrated genomic analysis of breast cancers.

Addou-Klouche L, Adélaïde J, Cornen S, Bekhouche I, Finetti P, Guille A, Sircoulomb F, Raynaud S, Bertucci F, Birnbaum D, Chaffanet M.

Balkan J Med Genet. 2012 Dec;15(Suppl):71-4. doi: 10.2478/v10034-012-0023-x.


Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase.

Brecqueville M, Rey J, Devillier R, Guille A, Gillet R, Adélaide J, Gelsi-Boyer V, Arnoulet C, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D, Murati A.

Haematologica. 2014 Jan;99(1):37-45. doi: 10.3324/haematol.2013.091454. Epub 2013 Aug 30.


Signaling pathway switch in breast cancer.

Guille A, Chaffanet M, Birnbaum D.

Cancer Cell Int. 2013 Jun 27;13(1):66. doi: 10.1186/1475-2867-13-66.


Comprehensive genome characterization of solitary fibrous tumors using high-resolution array-based comparative genomic hybridization.

Bertucci F, Bouvier-Labit C, Finetti P, Adélaïde J, Metellus P, Mokhtari K, Decouvelaere AV, Miquel C, Jouvet A, Figarella-Branger D, Pedeutour F, Chaffanet M, Birnbaum D.

Genes Chromosomes Cancer. 2013 Feb;52(2):156-64. doi: 10.1002/gcc.22015. Epub 2012 Oct 17.


A new case with 10q23 interstitial deletion encompassing both PTEN and BMPR1A narrows the genetic region deleted in juvenile polyposis syndrome.

Hiljadnikova Bajro M, Sukarova-Angelovska E, Adélaïde J, Chaffanet M, Dimovski AJ.

J Appl Genet. 2013 Feb;54(1):43-7. doi: 10.1007/s13353-012-0115-z. Epub 2012 Sep 21.


Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms.

Brecqueville M, Cervera N, Adélaïde J, Rey J, Carbuccia N, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D, Gelsi-Boyer V, Murati A.

Blood Cancer J. 2011 Aug;1(8):e33. doi: 10.1038/bcj.2011.31. Epub 2011 Aug 26. No abstract available.


Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms.

Brecqueville M, Adélaïde J, Bertucci F, Finetti P, Chaffanet M, Birnbaum D, Murati A.

Cell Cycle. 2012 Aug 15;11(16):3141-2. doi: 10.4161/cc.21114. Epub 2012 Jul 24. No abstract available.


Mutations and deletions of ARID1A in breast tumors.

Cornen S, Adelaide J, Bertucci F, Finetti P, Guille A, Birnbaum DJ, Birnbaum D, Chaffanet M.

Oncogene. 2012 Sep 20;31(38):4255-6. doi: 10.1038/onc.2011.598. Epub 2012 Jan 16. No abstract available.


Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer.

Sabatier R, Finetti P, Adelaide J, Guille A, Borg JP, Chaffanet M, Lane L, Birnbaum D, Bertucci F.

PLoS One. 2011;6(11):e27656. doi: 10.1371/journal.pone.0027656. Epub 2011 Nov 16.


[Genome: does a paucity of initiation events lead to fragility?].

Letessier A, Birnbaum D, Debatisse M, Chaffanet M.

Med Sci (Paris). 2011 Aug-Sep;27(8-9):707-9. doi: 10.1051/medsci/2011278011. Epub 2011 Aug 31. French. No abstract available.


Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes.

Brecqueville M, Cervera N, Gelsi-Boyer V, Murati A, Adélaïde J, Chaffanet M, Rey J, Vey N, Mozziconacci MJ, Birnbaum D.

Blood Cancer J. 2011 May;1(5):e18. doi: 10.1038/bcj.2011.15. Epub 2011 May 13. No abstract available.


[ZNF703: a novel oncogene involved in breast cancer].

Ginestier C, Sircoulomb F, Charafe-Jauffret E, Chaffanet M, Birnbaum D.

Med Sci (Paris). 2011 Apr;27(4):357-9. doi: 10.1051/medsci/2011274008. Epub 2011 Apr 28. French. No abstract available.


Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth.

Fournier G, Cabaud O, Josselin E, Chaix A, Adélaïde J, Isnardon D, Restouin A, Castellano R, Dubreuil P, Chaffanet M, Birnbaum D, Lopez M.

Oncogene. 2011 Sep 8;30(36):3862-74. doi: 10.1038/onc.2011.106. Epub 2011 Apr 11.


Genome profiling of pancreatic adenocarcinoma.

Birnbaum DJ, Adélaïde J, Mamessier E, Finetti P, Lagarde A, Monges G, Viret F, Gonçalvès A, Turrini O, Delpero JR, Iovanna J, Giovannini M, Birnbaum D, Chaffanet M.

Genes Chromosomes Cancer. 2011 Jun;50(6):456-65. doi: 10.1002/gcc.20870. Epub 2011 Mar 15.


High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes.

Bekhouche I, Finetti P, Adelaïde J, Ferrari A, Tarpin C, Charafe-Jauffret E, Charpin C, Houvenaeghel G, Jacquemier J, Bidaut G, Birnbaum D, Viens P, Chaffanet M, Bertucci F.

PLoS One. 2011 Feb 9;6(2):e16950. doi: 10.1371/journal.pone.0016950.


ZNF703 gene amplification at 8p12 specifies luminal B breast cancer.

Sircoulomb F, Nicolas N, Ferrari A, Finetti P, Bekhouche I, Rousselet E, Lonigro A, Adélaïde J, Baudelet E, Esteyriès S, Wicinski J, Audebert S, Charafe-Jauffret E, Jacquemier J, Lopez M, Borg JP, Sotiriou C, Popovici C, Bertucci F, Birnbaum D, Chaffanet M, Ginestier C.

EMBO Mol Med. 2011 Mar;3(3):153-66. doi: 10.1002/emmm.201100121. Epub 2011 Feb 15. Erratum in: EMBO Mol Med. 2011 Mar;3(3). doi:10.1002/emmm.201000121.


Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis.

Gonçalves A, Finetti P, Sabatier R, Gilabert M, Adelaide J, Borg JP, Chaffanet M, Viens P, Birnbaum D, Bertucci F.

Breast Cancer Res Treat. 2011 May;127(1):273-81. doi: 10.1007/s10549-010-1199-y. Epub 2010 Nov 11.


Genome profiling of ERBB2-amplified breast cancers.

Sircoulomb F, Bekhouche I, Finetti P, Adélaïde J, Ben Hamida A, Bonansea J, Raynaud S, Innocenti C, Charafe-Jauffret E, Tarpin C, Ben Ayed F, Viens P, Jacquemier J, Bertucci F, Birnbaum D, Chaffanet M.

BMC Cancer. 2010 Oct 8;10:539. doi: 10.1186/1471-2407-10-539.


ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.

Gelsi-Boyer V, Trouplin V, Roquain J, Adélaïde J, Carbuccia N, Esterni B, Finetti P, Murati A, Arnoulet C, Zerazhi H, Fezoui H, Tadrist Z, Nezri M, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D.

Br J Haematol. 2010 Nov;151(4):365-75. doi: 10.1111/j.1365-2141.2010.08381.x. Epub 2010 Sep 29.


BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer.

Sabatier R, Adélaïde J, Finetti P, Ferrari A, Huiart L, Sobol H, Chaffanet M, Birnbaum D, Bertucci F.

Genes Chromosomes Cancer. 2010 Dec;49(12):1143-51. doi: 10.1002/gcc.20822.


Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers.

Raynaud S, Carbuccia N, Colin C, Adélaïde J, Mozziconacci MJ, Metellus P, Chinot O, Birnbaum D, Chaffanet M, Figarella-Branger D.

Oncol Lett. 2010 Sep;1(5):883-884. Epub 2010 Sep 1.


Loss, mutation and deregulation of L3MBTL4 in breast cancers.

Addou-Klouche L, Adélaïde J, Finetti P, Cervera N, Ferrari A, Bekhouche I, Sircoulomb F, Sotiriou C, Viens P, Moulessehoul S, Bertucci F, Birnbaum D, Chaffanet M.

Mol Cancer. 2010 Aug 10;9:213. doi: 10.1186/1476-4598-9-213.

Supplemental Content

Loading ...
Support Center